Treatment of oral cancer using magnetized paclitaxel

18Citations
Citations of this article
32Readers
Mendeley users who have this article in their library.

Abstract

N,N'-Bis(salicylidene)ethylenediamine iron (Fe(Salen)) is an anti-cancer agent with intrinsic magnetic property. Here, we covalently linked Fe(Salen) to paclitaxel (PTX), a widely used anti-cancer drug, to obtain a magnetized paclitaxel conjugate (M-PTX), which exhibited magnetic characteristics for magnet-guided drug delivery and MRI visualization. M-PTX increased apoptosis and G2/M arrest of cultured human oral cancer cell lines in the same manner as PTX. Furthermore, marked contrast intensity was obtained in magnetic resonance imaging (MRI) of M-PTX. In a mouse oral cancer model, a permanent magnet placed on the body surface adjacent to the tumor resulted in distinct accumulation of M-PTX, and the anti-cancer effect was greater than that of M-PTX without the magnet. We believe that this strategy may improve future cancer chemotherapy by providing conventional anti-cancer drugs with novel functionalities such as magnet-guided drug delivery or MRI-based visualization/ quantitation of drug distribution.

Cite

CITATION STYLE

APA

Nakakaji, R., Umemura, M., Mitsudo, K., Kim, J. H., Hoshino, Y., Sato, I., … Ishikawa, Y. (2018). Treatment of oral cancer using magnetized paclitaxel. Oncotarget, 9(21), 15591–15605. https://doi.org/10.18632/oncotarget.24570

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free